An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease

Clinical trial NCT02485899 · COMPLETED

Trial details

NCT number: NCT02485899
Sponsor: BioMarin Pharmaceutical
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Jansky-Bielschowsky Disease Batten Disease Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 CLN2 Disease CLN2 Disorder

Start date: 2015-02-01
Primary completion: 2020-12-10
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.